


Amarin Corporation is a late-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin is developing AMR101, a prescription-grade omega-3 fatty acid, as a prescription medicine for the treatment of patients with very high triglyceride levels (≥ 500 mg/dL) and as a potentially first-in-class therapy for patients with high triglyceride levels (≥ 200 and <500 mg/dL) who are also on statin therapy for elevated LDL-cholesterol levels (mixed dyslipidemia).

Commercial Opportunity

Lipid management is evolving from a traditional focus solely on cholesterol management to include triglyceride (TG) management. Treatment therapies have emerged that address high TGs. However, those therapies, which currently include fibrates and prescription omega-3s, can elevate LDL-C ("bad cholesterol") by nearly 50% in patients with very high TGs.




AMR101 represents a new generation of lipid therapy that has demonstrated in two Phase 3 clinical trials to lower TGs without increasing LDL-C, and even lowers LDL-C under certain conditions.

Potential Markets

Hypertriglyceridemia refers to a condition in which patients have high blood levels of triglycerides and is recognized as an independent risk factor for cardiovascular disease. Based upon our Phase 3 clinical trial results, Amarin will seek approval for two indications that together target nearly 40 million U.S. and >100 million people worldwide with triglyceride levels ≥ 200 mg/dL, with the goal of expanding those potential markets beyond the limited market penetration of current therapies while pursuing multiple follow-on indications.

>100M People in Top 7 Markets for Initially Targeted Indications



Source: [DataMonitor](#) and Archives of Internal Medicine, 2009;139(6):572-578

Development Status: Phase 3 Complete and Successful

AMR101 has progressed through Phase 3 clinical development reporting positive, statistically significant top-line results for both of its two pivotal Phase 3 clinical trials MARINE (TG ≥ 500 mg/dL) and ANCHOR (TG ≥ 200 and <500 mg/dL and on statin therapy). Both trials were conducted under separate Special Protocol Assessment (SPA) agreements with FDA. Amarin also has next-generation lipid candidates under evaluation for preclinical development.

Clearly-Defined Regulatory Path

Amarin has submitted an NDA to the FDA seeking approval for the marketing and sale of AMR101 for treatment of patients with very high triglycerides (July 26, 2012 PDUFA date assigned). The submission is based on the entire data set from the Company's AMR101 development program, including safety and efficacy data from the Phase 3 MARINE and ANCHOR studies. The high triglycerides/mixed dyslipidemia indication will be pursued once an AMR101 clinical outcomes study is substantially underway.

Commercial Path Forward

As is the case with any pharmaceutical or biotechnology company with a valuable late stage asset like AMR101, the Company is focused on what it controls, self-commercialization. Amarin is also willing to consider other strategic options and will continue to evaluate and pursue commercial strategies for AMR101 that offer the best option for value creation.

SENIOR MANAGEMENT

Joseph Zakrzewski

Chairman and CEO

John Thero

President

Paul Huff

SVP, Chief Commercial Officer

Joseph Kennedy

SVP, General Counsel

Steve Ketchum

SVP, President of Research & Development

Stuart Sedlack

SVP, Corporate Development

Declan Doogan

Chief Medical Officer

BOARD OF DIRECTORS

Joseph Zakrzewski

Executive Chairman and CEO

Joseph Anderson, Ph.D.

Abingworth BioEquities

Lars Ekman, M.D., Ph.D.

Elan Corporation

Carl Gordon, Ph.D.

OrbiMed Advisors

James Healy, M.D, Ph.D.

Sofinnova Ventures

Jan van Heek

BioPoint Group

Patrick O'Sullivan

Independent Business Consultant

Kristine Peterson

Chief Executive Officer, Valeritas

Financial Snapshot (December 31, 2011)

Cash: \$116.6M*

Common Shares: 135.8M

Options: 11.9M

Warrants: 21.1M

Total: 168.8M

**Prior to \$150M convertible debt financing priced Jan 2012*

Amarin assumes no obligation to update this snapshot for new information or future events or developments. Investment in Amarin involves substantial risks and uncertainties as described in Amarin's Annual Report as filed with the U.S. Securities and Exchange Commission.

“Both MARINE and ANCHOR trial results exceeded our expectations and we believe clearly differentiate AMR101 from other triglyceride lowering therapies, positioning Amarin to be both best-in-class and first-in-class for treating the high triglyceride patient population. At the same time, the significant reductions seen in the new data on other lipid biomarkers would suggest that pure EPA can potentially provide broader cardiovascular benefit.”

Joseph Zakrzewski –Chairman and CEO, Amarin

History of Positive Achievement

All 2010 – 2011 Milestones Achieved
Ahead of or on Schedule

MARINE and ANCHOR Trial Results

REDUCE-IT Commenced

Global Supply Chain Expansion

NDA Submitted and Accepted

Looking Ahead in 2012

**ANCHOR
Data Publication**

**Prosecution of 16 U.S.
Patent Applications**

**MARINE NDA
PDUFA Date: July 26, 2012
Potential H2, 2012 approval**

NCE Status Determination

**REDUCE-IT Substantially
Underway**

sNDA for ANCHOR Indication



Amarin Corporation Contact

Corporate Headquarters

2 Pembroke House
Upper Pembroke Street 28-32
Dublin 2, Ireland
Tel: +353 (0) 1 6699 020

US Offices

1430 Route 206
Bedminster, NJ 07921
USA
Tel: (908) 719-1315

475 Bridge Street
Groton, CT 06340
USA
Tel: (860) 572-4979

This document contains forward-looking statements, including statements regarding timing of regulatory milestones. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other matters can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.